drugset / Trial / NCT06551415

Dabigatran Versus Apixaban in Cerebral Venous Thrombosis

NCT06551415

Phase 3 Recruiting 200 enrolled Kafrelsheikh University
RandomizedParallel-groupDouble-blindTreatment

Summary

Along with the current clinical trial, the efficacy and safety of a 150 mg Bid dabigatran administered within 24 hours of randomization after having first-ever cerebral venous thrombosis compared to apixaban 5mg Bid were assessed through rate of recurrent VTE, mRS, rate of venous recanalization, HIT score, MoCA test, and central and peripheral hemorrhagic complications

Timeline

Start
2021-08-01
Primary completion
2024-09-01
Completion
2024-10-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Apixaban Small molecule 5 mg
Comparator Dabigatran etexilate Unknown 150 mg